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Table 1.  Patient characteristics (n=94)
Parameter Number
Age, median (range) (years) 70 (34–87)
Sex, male, n  (%) 58 (62)
Tumor size, median (IQR) (mm) 25 (20-35)
Tumor location, n  (%)
  Ph/ Pb/ Pt 27 (29)/ 56 (59)/ 11 (11)
Tumor marker, median (IQR)
  CEA, ng/mL 3.3 (2-5.9)
  CA19-9, U/mL 113 (15-324)
  DUPAN-2, U/mL 110 (25-354)
  Span-1, U/mL 53 (17-147)
T stagea
 1/2/3 5 (5)/7 (8)/82 (87)
N stagea
 0/1 46 (49)/48 (51)
Pathological stagea, n  (%)
ⅠA /ⅠB/ⅡA/ⅡB 4 (4)/5 (5)/37 (40)/48 (51)
Adjuvant chemotherapy, n  (%) 81 (86)
Median interval between FNA and surgery (IQR), days 15 (11-21)
Median overall survival (IQR), days 864 (525-2462)
IQR: interquartile range, Ph: pancreatic head, Pb: pancreatic body, Pt: pancreatic tail, 
CEA: carcinoembryonic antigen, CA19-9: carbohydrate antigen 19-9,
DUPAN-2: duke pancreatic monoclonal antigen type 2, Span-1: serum pancreas antigen type
FNA: fine-needle aspiration
a UICC 7th International Union against Cancer TNM Classification of Malignant Tumors 7th ed


















Table 2c. The diagnostic accuracy of FNA for evaluating the PD-L1 expression on resected specimens (n=94)
Cut-off point ≥ 5% on resected











Cut-off point ≥ 10% on











PPV: positive predictive value, NPV: negative predictive value, CI: confidence interval, FNA: fine-needle aspiration, 













Table 3. Relationship between the PD-L1 expression and clinicopathological features
Variable PD-L1 expression (+)(n = 11)
PD-L1 expression (-)
(n = 83) P  value
Age, median (range) (years)  71 (57-81) 70 (34-87) 0.85
Sex, male/female 7/4   51/32 0.89
Tumor size, median (IQR) (mm) 28 (22-42) 25 (20-31) 0.11
Tumor location, Ph/Pbt 5/6 47/32 0.37
Tumor marker, median (IQR)
 CEA, ng/mL 5.1 (2.6-7.8) 3.1 (1.9-5.3) 0.2
 CA19-9, U/mL 247 (37-596) 71 (12-290) 0.04
 DUPAN-2, U/mL 68 (25-334) 113 (25-362) 0.89
 Span-1, U/mL 115 (50-343) 48 (17-145) 0.18
Median no. of needle passes (IQR) 2 (2-3) 2 (2-3) 0.87
Selected FNA needle, 22/25G 7/4 68/15 0.16
Number of tumor cells counted for IHC on FNA specimens (IQR) 399 (193-607) 530 (235-1123) 0.47
 T stage,  1/2/3 0/1/10 5/6/72 0.7
 N stage , 0/1 6/5 40/43 0.69
Adjuvant therapy, yes/no 8/3 73/10 0.17
Median interval between FNA and surgery (IQR), days 13 (11-27) 15 (11-21) 0.81
Median overall survival, days 831 915 0.77
IQR: interquartile range, Ph: pancreatic head, Pbt, pancreatic body and tail, FNA: fine-needle aspiration
IHC: immunohistochemistry, PD-L1: programmed death ligand 1
PD-L1 expression (+): PD-L1 was expressed ≥ 10% on resected specimen
